Isolation and Characterization of the Acadevirus Members BigMira and MidiMira Infecting a Highly Pathogenic Proteus

Jéssica Duarte da Silva1, Lene Bens2, Adriele J do Carmo Santos1

  • 1Laboratory of Molecular Immunovirology, Department of Microbiology, Federal University of Viçosa, Viçosa 36570-900, MG, Brazil.

Microorganisms
|September 28, 2023
PubMed

Insights

Two novel phages, BigMira and MidiMira, show potential for treating Proteus mirabilis infections, including challenging multidrug-resistant strains. These phages offer a promising alternative to antibiotics for catheter-associated urinary tract infections (CAUTIs).

Area of Science:

  • Microbiology
  • Bacteriology
  • Virology

Background:

  • Proteus mirabilis is a major cause of catheter-associated urinary tract infections (CAUTIs), exacerbated by antibiotic resistance.
  • Bacteriophage therapy is regaining interest as a strategy against multidrug-resistant bacterial pathogens.

Purpose of the Study:

  • To characterize the biological and genomic features of two novel P. mirabilis phages, BigMira and MidiMira.
  • To analyze the genomic diversity of clinical P. mirabilis strains and correlate it with phage host range.

Main Methods:

  • Isolation and characterization of BigMira and MidiMira phages.
  • Comparative genomic analysis of P. mirabilis strains.
  • Assessment of phage depolymerase activity and host range.

Main Results:

  • BigMira and MidiMira are Acadevirus phages highly similar to each other, with minor tail fiber mutations affecting depolymerase activity.
  • Clinical P. mirabilis strains exhibit varied antibiotic resistance and lipopolysaccharide locus profiles, influencing phage host range.
  • The P. mirabilis isolation strain harbors numerous antimicrobial resistance genes, underscoring treatment challenges.

Conclusions:

  • BigMira and MidiMira phages demonstrate potential as therapeutic agents against P. mirabilis infections.
  • Genomic variations in P. mirabilis impact susceptibility to phage therapy.
  • Phage therapy presents a viable option for combating multidrug-resistant P. mirabilis infections.